1. Catalog
  2. The Lead Episode 24: A Discussion of Catheter Abla ...
The Lead Episode 24: A Discussion of Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation
Description
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by Kolade Muchaili Agboola, MD, and Akshay Suvas Desai, MD, MPH, of Brigham and Women's Hospital to discuss the results and implications of the CASTLE-HTx trial.
Learning Objectives
  • To understand the methods and results of the CASTLE-HTx trial
  • To recognize the limitations of the CASTLE-HTx trial and how the trial contributes to our understanding of the role of ablation for the management of atrial fibrillation in patients with severe HF.
Article Authors and Podcast Contributors
Article Authors
Sohns C, Fox H, Marrouche NF, Crijns HJ, Costard-Jaeckle A, Bergau L, Hindricks G, Dagres N, Sossalla S, Schramm R, Fink T, on behalf of the CASTLE-HTx Investigators

Podcast Contributors
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital
Kolade Muchaili Agboola, MD, of Brigham and Women’s Hospital
Akshay Suvas Desai, MD, MPH, of Brigham and Women's Hospital
Disclosures

 

All relevant financial relationships have been mitigated.

Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic

Contributor Disclosure(s):
K. Agboola: No relevant financial relationships with ineligible companies to disclose. 
A. Desai: Honoraria/Speaking/Consulting Fee: Abbott, Novartis, AstraZeneca, BioFourmis, Regeneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlaxoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal; Research (Contracted Grants for PIs Named Investigators Only): Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Novartis


Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose. 
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
Summary
Availability:
On-Demand
Cost:
FREE
Credit Offered:
No Credit Offered
Recommended